À propos de deux cas de lymphome mammaire sur coque périprothétique : un diagnostic difficile ; une pathologie méconnue

Ivaldi, C.; Perchenet, Anne-Sophie; Jallut, Y.; Casanova, Dominique

doi:10.1016/j.anplas.2013.04.003

Cited by 20 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, 16 patients have died from BIA-ALCL, and each had extracapsular involvement. 31,60,80,81 Furthermore, among patients who had advanced disease, many had a substantial delay in either diagnosis or implant removal.…”

Section: Prognosismentioning

confidence: 99%

Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management

et al. 2020

View full text Add to dashboard Cite

Worldwide, millions of women live with breast implants. Therefore, it is important that physicians be aware of an uncommon but possibly serious complication arising from breast implants: breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Breast implant–associated anaplastic large-cell lymphoma most commonly presents as a delayed fluid collection around a textured breast implant or as a mass in the capsule surrounding the implant. The exact pathogenesis of the disease remains unclear. The neoplastic cells of BIA-ALCL show strong uniform staining for CD30 and are consistently negative for activin receptor-like kinase 1. Patients with confirmed cases should be referred to a lymphoma specialist or breast medical oncologist for a complete oncologic evaluation before any surgical intervention. For disease confined to the fluid accumulation or capsule, or both, surgical removal of the implant and complete capsulectomy is the preferred treatment. Postoperative chemotherapy or radiation, or both, are not considered necessary for patients with limited-stage disease and are reserved for advanced disease stages. Generally, BIA-ALCL is a local disease that follows an indolent course and has an excellent prognosis. Although complete remission of disease has occurred in patients with BIA-ALCL, median overall survival is reduced. As of March 2018, approximately 529 unique, confirmed BIA-ALCL cases had been reported in 23 countries. To date, 16 patients have died from BIA-ALCL, and all had extracapsular involvement. The aim of this article is to summarize the diagnosis, evaluation, and management of BIA-ALCL, based on established guidelines, for all practitioners who may care for patients with breast implants.

show abstract

Section: Prognosismentioning

confidence: 99%

Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management

et al. 2020

View full text Add to dashboard Cite

show abstract

“…2 b). Evaluation with PET can vary from diffuse [ 10 – 12 ] to focal [ 13 , 14 ] FDG uptake surrounding the implant or its capsule. FDG uptake can also appear in regional lymph nodes, suggestive of metastatic progression [ 10 , 14 – 16 ].…”

Section: Casementioning

confidence: 99%

“…These figures are similar or better than CT or magnetic resonance imaging (MRI) in effusion detection [ 7 ]. b MRI provides characterisation of the implant’s capsule, defining enhancement and thickening [ 14 , 15 ]. This makes it the modality of choice for defining the implant capsule ( white arrow ) [ 7 ].…”

Section: Casementioning

confidence: 99%

See 1 more Smart Citation

Breast implant-associated anaplastic large cell lymphoma: a pictorial review

Chacko

Lloyd

2018

Insights Imaging

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a newly described and rare T-cell lymphoma of the breast. Since 2007, there have been 56 cases of confirmed BIA-ALCL in Australia and New Zealand. The incidence is believed to be on the rise as the prevalence of elective breast implantation increases. In 2016, the World Health Organization (WHO) classified BIA-ALCL as a recognised entity and emphasised the importance of surgical management of the disease. BIA-ALCL typically presents as a delayed, non-infective fluid collection around a textured breast implant or residual fibrous scar capsule. The mean age of presentation is 47 years, with an average time frame of 7.5 years following breast implantation. Although rare, BIA-ALCL is increasing in incidence. To avoid delays in diagnosis, radiologists should consider this form of lymphoma in the differential of any non-acute peri- or post-prosthetic effusion, and suggest cytological evaluation, so as not to miss this rare but important diagnosis.Teaching Points• BIA-ALCL is a newly described and rare T-cell lymphoma of the breast.• Since 2007, there have been 56 cases of confirmed BIA-ALCL in Australia and New Zealand.• BIA-ALCL presents as a delayed, non-infective fluid collection.• The effusion typically accumulates around a textured breast implant or residual fibrous capsule.

show abstract

“…On note depuis quelques années l'apparition d'un type particulier de lymphome mammaire, le lymphome T anaplasique à grandes cellules, se développant au contact de prothèses mammaires [1][2][3]. Il s'agit d'un type particulier de lymphome non hodgkinien, caractérisé par l'expression de l'antigène CD30 et n'exprimant pas la protéine ALK [4].…”

Section: Introductionunclassified

À propos d’un cas de lymphome anaplasique à grandes cellules diagnostiqué après explantation de prothèse mammaire

Henry

Kerfant

Blanc

et al. 2015

Annales de Chirurgie Plastique Esthétique

View full text Add to dashboard Cite

À propos de deux cas de lymphome mammaire sur coque périprothétique : un diagnostic difficile ; une pathologie méconnue

Cited by 20 publications

References 20 publications

Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management

Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management

Breast implant-associated anaplastic large cell lymphoma: a pictorial review

À propos d’un cas de lymphome anaplasique à grandes cellules diagnostiqué après explantation de prothèse mammaire

Contact Info

Product

Resources

About